^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TheraSphere (yttrium 90 microspheres)

    Associations

    News

    Trials
    Company:
    Boston Scientific
    Drug class:
    Beta radiation emitter
    Related drugs:
    Associations

    News

    Trials
    28d
    EMERALD-Y90: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (clinicaltrials.gov)
    P2, N=60, Recruiting, AstraZeneca | N=100 --> 60
    Enrollment change
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • TheraSphere (yttrium 90 microspheres)
    2ms
    Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk (clinicaltrials.gov)
    P2, N=84, Suspended, Northwestern University | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • TheraSphere (yttrium 90 microspheres)
    3ms
    Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Miami | Not yet recruiting --> Recruiting | Trial completion date: Aug 2030 --> Nov 2030 | Initiation date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2030 --> Nov 2030
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    Stivarga (regorafenib) • TheraSphere (yttrium 90 microspheres)
    3ms
    ROWAN: TheraSphere With Durvalumab and Tremelimumab for HCC (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Boston Scientific Corporation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • TheraSphere (yttrium 90 microspheres)
    4ms
    Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=64, Not yet recruiting, University of California, San Francisco
    New trial
    |
    TheraSphere (yttrium 90 microspheres)
    7ms
    FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (clinicaltrials.gov)
    P1, N=36, Recruiting, Boston Scientific Corporation | Active, not recruiting --> Recruiting | N=12 --> 36 | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    8ms
    Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, University of Miami
    New P2 trial
    |
    Stivarga (regorafenib) • TheraSphere (yttrium 90 microspheres)
    8ms
    BEAT-UT7: Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria (clinicaltrials.gov)
    P2, N=100, Recruiting, Seoul National University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TheraSphere (yttrium 90 microspheres)
    10ms
    Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk (clinicaltrials.gov)
    P2, N=84, Suspended, Northwestern University | Trial completion date: Jul 2025 --> Jul 2026 | Recruiting --> Suspended | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial suspension • Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • TheraSphere (yttrium 90 microspheres)
    10ms
    VOYAGER: First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device (clinicaltrials.gov)
    P=N/A, N=36, Recruiting, Boston Scientific Corporation | Active, not recruiting --> Recruiting
    Enrollment open
    |
    TheraSphere (yttrium 90 microspheres)
    10ms
    PROACTIF: Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P=N/A, N=1247, Completed, Boston Scientific Corporation | Active, not recruiting --> Completed | N=500 --> 1247 | Trial primary completion date: Jan 2024 --> Dec 2024
    Trial completion • Enrollment change • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    11ms
    BEAT-UT7: Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Seoul National University Hospital
    New P2 trial
    |
    TheraSphere (yttrium 90 microspheres)